Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

56
Biotech: Take It On The Run

2018-07-05 seekingalpha
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

33
MGTX / MeiraGTx Holdings plc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-22 fintel.io
MeiraGTx Holdings plc (NASDAQ:MGTX) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . MeiraGTx Holdings plc (NASDAQ:MGTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
SGEN KDMN MGTX ONCE

29
KDMN / Kadmon Holdings, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 2 TO SCHEDULE 13G (Passive Investment)

2018-06-22 sec.gov
Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
KDMN

34
KDMN / Kadmon Holdings, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 2 TO SCHEDULE 13G (Passive Investment)

2018-06-22 sec.gov
Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
KDMN

28
Kadmon Holdings: Secondary Offering Points To Revaluation Opportunity

2018-06-19 seekingalpha
The stock rose significantly after my first article but since has pulled back to square one.
KDMN FVC

29
KDMN / Kadmon Holdings, Inc. / GOLDENTREE ASSET MANAGEMENT LP - AMENDMENT 7 TO SCHEDULE 13D (Activist Investment)

2018-06-18 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
KDMN

31
KDMN / Kadmon Holdings, Inc. / GOLDENTREE ASSET MANAGEMENT LP - AMENDMENT 7 TO SCHEDULE 13D (Activist Investment)

2018-06-18 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
KDMN

240
SPOT / Spotify Technology S.A. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-15 fintel.io
Spotify Technology S.A. (NYSE:SPOT) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Spotify Technology S.A. (NYSE:SPOT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
PRTO SPOT AAPL KDMN GALPW GALE MGTX STML ONCE GALEW

28
KDMN / Kadmon Holdings, Inc. FORM DEF 14A

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
KDMN

32
KDMN / Kadmon Holdings, Inc. FORM DEFA14A

2018-06-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
KDMN

28
KDMN / Kadmon Holdings, Inc. FORM 8-K (Current Report)

2018-06-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi
KDMN

27
KDMN / Kadmon Holdings, Inc. FORM 8-K (Current Report)

2018-06-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi
KDMN

28
KDMN / Kadmon Holdings, Inc. FORM 424B5 (Prospectus)

2018-06-12 sec.gov
Filed Pursuant to Rule 424(b)(5) Registration No. 333-222364
KDMN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 48283N106